Tweet
Antiviral Res. 2019 Apr 8. pii: S0166-3542(19)30158-5. doi: 10.1016/j.antiviral.2019.04.006. [Epub ahead of print]
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
Beigel JH1, Nam HH2, Adams PL3, Krafft A4, Ince WL5, El-Kamary SS5, Sims AC6.
Author information
Abstract
The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.
Copyright ? 2019. Published by Elsevier B.V.
KEYWORDS:
Antiviral therapy; Coronavirus; Host-directed therapeutics; Influenza; Respiratory syncytial virus
PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
Beigel JH1, Nam HH2, Adams PL3, Krafft A4, Ince WL5, El-Kamary SS5, Sims AC6.
Author information
Abstract
The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.
Copyright ? 2019. Published by Elsevier B.V.
KEYWORDS:
Antiviral therapy; Coronavirus; Host-directed therapeutics; Influenza; Respiratory syncytial virus
PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006